Lung Deposition of the BDP/Formoterol Combination Administered Via the NEXT DPI in Healthy, Asthmatic and COPD Patients
In-vivo Deposition Measurement of Beclometasone and Formoterol After Inhalation of a Single Dose of the Combination BDP Plus Formoterol NEXT DPI in Healthy Volunteers, Asthmatic and COPD Patients.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Gauting, Germany, 82131
- Inamed Research GmbH & Co. KG
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Healthy volunteers:
- Males and females aged 18-65 years;
- Body Mass Index (BMI) between 18.0 and 28.0 kg/m2;
- Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year;
- Normal blood pressure and heart rate;
- Normal electrocardiogram (ECG,12 lead);
- Normal laboratory tests;
Patients with Asthma:
- Males and females aged 21-65 years;
- BMI between 18.0 and 28.0 kg/m2;
- Non- or ex-smokers who smoked < 5 pack years and stopped smoking > 1 year;
- Normal blood pressure and heart rate;
- Normal ECG (12 lead);
- FEV1 ≥ 30% and < 80% of predicted according to European Coal and Steel Community values (ECSC)
- Reversibility of FEV1 ≥ 12% and at least 200 ml of the initial value 15 minutes after inhalation of 200 µg Salbutamol;
Patients with COPD:
- Males and females aged 40 - 70 years
- BMI between 18.0 and 30.0 kg/m2;
- Normal blood pressure and heart rate;
- Normal ECG (12 lead);
- Stable COPD within the past 4 weeks;
- Post bronchodilator FEV1 between 30% and 50% predicted values (ECSC);
- Post bronchodilator FEV1/FVC < 0.70 (absolute value);
- Minimum smoking history of 10 pack-years;
Exclusion Criteria:
All subjects:
- Blood donation or blood loss in the previous 8 weeks;
- Positive HIV1 or HIV2 serology;
- Positive acute or chronic Hepatitis B or Hepatitis C;
- Unsuitable veins for repeated venipuncture;
- Female patients: pregnant, positive pregnancy test, lactating mother or lack of efficient contraception.
- History of substance abuse or positive urine drug screen;
- Abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;
- Uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric clinically significant disorder;
- Participation in another clinical trial in the previous 8 weeks; participation in study using radioactive material within 1 calendar year;
- Known sensitivity to Formoterol or Beclometasone or any of the excipients;
- Concomitant severe diseases or diseases which are contra indications for the use of inhaled Beta-2-agonist or steroids;
- Use of any prescription drug for which concomitant beta-agonist or steroid administration are contraindicated;
- Recent relevant infectious disease (less than two months);
- Flu vaccination or other vaccination within 4 weeks prior to the screening visit;
Additional exclusion criteria for healthy volunteers:
- Lung function measurements outside normal limits (normal values: FEV1/FVC > 0.70 and FEV1 and FVC > 80% for the ECSC predicted values);
Additional exclusion criteria for patients with Asthma:
- Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months;
- Life-threatening/unstable respiratory status within the previous 30 days;
- Requirement of supplemental oxygen therapy;
- Change in dose or type of any medications for asthma within 4 weeks prior to the screening visit;
- Asthma exacerbation within the 4 weeks prior to inclusion.
Additional exclusion criteria for patients with COPD:
- Use of systemic steroids 4 weeks prior to inclusion (injectable depot steroids 6 weeks) or more than 3 periods during the last 6 months;
- Life-threatening/unstable respiratory status within the previous 30 days;
- Requirement of supplemental oxygen therapy;
- Change in dose or type of any medications for COPD within 4 weeks prior to the screening visit;
- COPD exacerbation within the 4 weeks prior to inclusion;
- History of asthma or any chronic respiratory diseases other than COPD.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: BDP/formoterol NEXT DPI
Radiolabelled BDP/formoterol 100/6 µg dry powder administered via the NEXT inhaler
|
Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lung deposition of BDP and Formoterol (expressed as % of emitted dose) when inhaled using the NEXT dry powder inhaler
Time Frame: Immediately after dosing
|
Calculated using the individual Gamma camera images and the regions of interest defined from the 81mKrypton-ventilation scan.
|
Immediately after dosing
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Lung function parameters
Time Frame: over 24 h post dose
|
over 24 h post dose
|
|
Distribution of lung deposition
Time Frame: Immediately after dosing
|
Immediately after dosing
|
|
Extrathoracic deposition
Time Frame: Immediately after dosing
|
Immediately after dosing
|
|
Exhaled activity
Time Frame: Immediately after dosing
|
Immediately after dosing
|
|
Plasma pharmacokinetics of formoterol, BDP and its monopropionate metabolite (B17MP)
Time Frame: over 24 h post dose
|
over 24 h post dose
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Thomas Meyer, MD, Inamed Research GmbH & Co. KG
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- CCD-0815-PR-0011
- 2009-010267-17 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.